| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Drug Manufacturers - General (Healthcare sector), NSRX's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 163.5K | $507.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Teleman Dan Benjamin | Chief Executive Officer | Buy | 6,550 | $3.10 | $20,305.00 | +4.2% | - | - | |
| Apr 22, 2026 | Teleman Dan Benjamin | Chief Executive Officer | Buy | 2,900 | $3.76 | $10,904.00 | +1.9% | -22.1% | - | |
| Mar 31, 2026 | Teleman Dan Benjamin | Chief Executive Officer | Buy | 15,000 | $2.04 | $30,600.00 | +240.2% | - | - |